TransMedics (TMDX) is a publicly traded Healthcare sector company. As of May 21, 2026, TMDX trades at $68.09 with a market cap of $2.36B and a P/E ratio of 13.62. TMDX moved +2.92% today. Year to date, TMDX is -46.15%; over the trailing twelve months it is -45.47%. Its 52-week range spans $55.00 to $160.80. Analyst consensus is buy with an average price target of $130.80. Rallies surfaces TMDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes TMDX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $68.09 |
| Market Cap | $2.36B |
| P/E Ratio | 13.62 |
| EPS | $5.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $160.80 |
| 52-Week Low | $55.00 |
| Volume | 2.78K |
| Avg Volume | 0 |
| Revenue (TTM) | $635.89M |
| Net Income | $171.92M |
| Gross Margin | 59.09% |
11 analysts cover TMDX: 0 strong buy, 7 buy, 4 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $130.80.